Skip to content

Association of chronic inflammation and bone outcomes in postmenopausal women modulated by vitamin D

Association of chronic inflammation and bone outcomes in postmenopausal women modulated by vitamin D

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105193
Enrollment
Unknown
Registered
2025-06-30
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D deficiency

Interventions

Observation group (vitamin D2 supplementation):None

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
45 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Postmenopausal women >=45 years of age; (2) Without elevated ESR or CRP; (3) Vitamin D deficiency [25OHD < 20ng/mL (50nmol/L)].

Exclusion criteria

Exclusion criteria: (1) Vitamin D supplementation in or use of drugs affecting vitamin D metabolism (e.g., antiepileptic drugs) in the last six months; (2) Patients with a significant difference in daylight hours in the last three months, such as a beach holiday or absolute bed rest; (3) Injections of bisphosphonate, denosumab, teriparatide 1 or more times or receiving oral bisphosphonate for 6 months or more in the last three years; (4) Have a history of chronic liver disease, kidney disease, tumour, or recent impaired liver or kidney function; (5) Have severe gestational disease, history of gastrointestinal surgery, or long-term vegetarian diet; (6) Have autoimmune disease, chronic inflammatory disease, or recent acute inflammatory disease; (7) Have a history of anti-inflammatory drug, glucocorticoid or immunosuppressant use in the last three months; (8) Having metabolic bone diseases other than osteoporosis, such as Paget's disease of bone, hyperparathyroidism, and hypoparathyroidism; (9) Any other patients who, in the judgement of the investigator, are unsuitable as subjects.

Design outcomes

Primary

MeasureTime frame
Serum 25-hydroxy-vitamin D;

Secondary

MeasureTime frame
Serum calcium;Serum phosphate;Parathyroid hormond;Bone mineral density;Procollagen type I N-terminal propeptide;Osteocalcin;Carboxy-terminal cross-linked telopeptide of type 1 collagen;Complete blood count;Erythrocyte sedimentation rate;Interleukin-1ß;Interleukin-6;Tumor necrosis factor-a;Interleukin-17A;Interferon-?;Transforming growth factor-ß;

Countries

China

Contacts

Public ContactYue Hua

Shanghai Sixth People's Hospital

yueyinglonghua@163.com+86 189 3017 2517

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026